Osurnia® (florfenicol, terbinafine, betamethasone acetate)
Osurnia is indicated for the treatment of otitis externa in dogs associated with susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatitis).
| Active(s)/Ingredient(s): | Florfenicol, Terbinafine, Betamethasone acetate |
| Pack size(s): | 2 - 1 mL, 20 - 1 mL |
| Documents: | Package insert get_app SDS get_app |
Important safety information
As with all drugs, side effects may occur. In a field study and post-approval experience the most common adverse reactions reported were vomiting, increased liver enzymes and loss of hearing. Other adverse events reported post-approval are ear discharge, ear irritation and pain, head shaking, head tilt, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, nystagmus, tympanic rupture, and facial paralysis.
OSURNIA® should be administered by a veterinary professional. Do not use in dogs with known tympanic perforation or a hypersensitivity to florfenicol, terbinafine or corticosteroids. OSURNIA may cause eye injury and irritation. Wear eye protection when administering OSURNIA and restrain the dog to minimize post-application head shaking. Do not use in cats. Refer to the prescribing information for complete details or visit www.dechra‐us.com.